Social Capital Suvretta Holdings Shares Up 63%; The Business Combination Between Co And Akili Closed Today, Aug. 19, 2022
$DNAA
Social Capital Suvretta Holdings Shares Up 63%; The Business Combination Between Co And Akili Closed Today, Aug. 19, 2022
Save time and jump to the most important pieces.
SC 13G - Akili, Inc. (0001850266) (Subject)
SC 13D - Akili, Inc. (0001850266) (Subject)
SC 13G - Akili, Inc. (0001850266) (Subject)
424B3 - Akili, Inc. (0001850266) (Filer)
8-K - Akili, Inc. (0001850266) (Filer)
424B3 - Akili, Inc. (0001850266) (Filer)
Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where
Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
3/A - Akili, Inc. (0001850266) (Issuer)
Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac
Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022. Akili raised more than $163 million from the
New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta H
In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co
Akili's leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depression Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in
Gainers GigaCloud Technology Inc (NASDAQ:GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) shares gained 80.2% to close at $0.91 after the company announced a marketing authorization application for pegzilarginase for the treatment of Arginase 1 deficiency has been submitted to and successfully validated by the European Medicines Agency. Social Capital Suvretta Holdings Corp. I (NASDAQ:DNAA) jumped 48.3% to settle at $14.07 following the completion of the SPAC merger with Akili. Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose 40.4% to close at $59.55 after the company announce